Search Results
Results 951 - 1000 of 1467
< 15 16 17 18 19 20 21 22 23 24 25 >
Stubbs P - - 1998
AIMS: Raised lipoprotein(a) concentrations are considered to be a risk factor for atherothrombotic diseases. We examined whether baseline concentrations were a risk factor for an adverse outcome in patients admitted with acute coronary syndromes. METHODS AND RESULTS: Five hundred and nineteen patients admitted with suspected acute coronary syndromes were studied ...
Kutsumi Y - - 1998
Low density lipoprotein (LDL) apheresis is one type of therapy currently being used for coronary artery disease; however, there has been no study to compare the effectiveness of this therapy with the effectiveness of other treatments, such as coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA). In ...
Aronow W S - - 1998
A prospective study of 500 consecutive persons (aged 60 years with Q-wave myocardial infarction admitted to a long-term health care facility) investigated the prevalence of the use of a lipid-lowering drug at the time of admission in persons with a fasting serum low-density lipoprotein (LDL) cholesterol >125 mg/dl measured the ...
van der Weijden T - - 1998
STUDY OBJECTIVE: To investigate and evaluate published data on cost effectiveness of cholesterol lowering interventions, and how this information could be interpreted in a rational approach of cholesterol management in general practice. DESIGN: A systematic review of the literature. SETTING: No restriction on setting. MATERIALS: Papers reporting on the cost ...
Rifkind B M - - 1998
Much diverse evidence suggests that the plasma levels of low-density lipoprotein (LDL) cholesterol play a causal role in the pathogenesis of atherosclerotic coronary heart disease. Until recently, clinical trials of LDL lowering, while showing significant reductions in coronary heart disease (CHD) rates, were not entirely convincing and left some questions ...
Oster G - - 1998
The first formal economic evaluation of a lipid-lowering intervention was conducted almost 20 years ago. The field exploded in the mid-1980s following the publication of findings from the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), in which the bile-acid sequestrant, cholestyramine, was reported to reduce the incidence of coronary ...
Farnier M - - 1998
Hyperlipidemia is recognized as one of the major risk factors for the development of coronary artery disease and progression of atherosclerotic lesions. Dietary therapy together with hypolipidemic drugs are central to the management of hyperlipidemia, which aims to prevent atherosclerotic plaque progression, induce regression, and so decrease the risk of ...
Straube R - - 1998
This paper reports 2 years' experience with lipoprotein (a) (Lp[a]) immunapheresis which was successfully handled on a now 40-year-old patient with familial Lp(a) hyperlipoproteinemia inducing severe coronary heart disease with 2 myocardial infarctions and diffuse coronary sclerosis. Continued treatment by Lp(a) immunabsorption with specific sheep antibodies reduced stenosis in coronary ...
Shepherd J - - 1998
Few areas in medicine offer such an impressive portfolio of evidence of clinical benefit as does the implementation of statins in the avoidance of coronary heart disease. The West of Scotland Coronary Prevention Study and the Air Force Coronary Atherosclerosis Prevention Study together have triggered a fundamental reappraisal of the ...
Masuoka H - - 1998
BACKGROUND: There is as yet no definite consensus on the predictive value of the various lipid profiles and fibrinolytic parameters that became available in clinical use recently for coronary artery disease. METHODS: Levels of lipoprotein(a), high-density lipoprotein cholesterol (HDL-C), remnant-like particles cholesterol (RLP-C), tissue plasminogen activator (TPA), TPA inhibitor, antithrombin ...
Ariyo A - - 1998
BACKGROUND: Previously reported data from the Physicians' Health Study indicate that there is no association between lipoprotein (a) level and subsequent risk of myocardial infarction among members of a large cohort of middle-aged men followed up prospectively for an average of 60.2 months. OBJECTIVE: To investigate whether this null finding ...
Kovanen P T - - 1998
BACKGROUND: Immune mechanisms have been suggested to play an important role in the development of coronary atherosclerosis and its thrombotic complications. We evaluated the predictive value of the levels of various serum immunoglobulin classes in middle-aged men at increased risk of myocardial infarction. METHODS: Using nested case-control design and logistic ...
Richter W O - - 1998
Low-density lipoprotein (LDL) apheresis is a potent treatment for patients with coronary heart disease and severe hereditary forms of LDL hypercholesterolemia not adequately responsive to drug treatment. Until now, the beneficial effect of aggressive reduction of LDL cholesterol by LDL apheresis on the course of coronary heart disease has been ...
Dincić D - - 1998
Atherosclerotic changes on the coronary arteries are the basis of the ischemic heart disease. It is assumed that the initial changes in this process occur as a consequence of the lipid peroxidation in the vessel wall. We estimated this process through the level of malondialdehyde (MDA) in the serum of ...
Castelli W - - 1998
There is a long history to our understanding of the biological basis of lipoproteins in cardiovascular disease and to the key epidemiological studies in this field. Building on a wealth of laboratory evidence explaining the role of cholesterol and lipoproteins in the pathogenesis of atherosclerosis, epidemiological studies have characterized associations ...
Mellwig K P - - 1998
A concomitant phenomenon of hypercholesterolemia is reduced coronary vasodilatation capacity due to disturbed endothelial function. Endothelial function can be partially or completely normalized by reducing cholesterol levels through drug therapy, but it is still unclear how rapidly this desired effect is achieved. An interval of between weeks and months has ...
Shepherd J - - 1998
The West of Scotland Coronary Prevention Study (WOSCOPS), a placebo-controlled 5-year cohort study, demonstrated that the use of pravastatin decreased low density lipoprotein (LDL) levels and associated risk of myocardial infarction. The rate of occurrence of coronary events, however, was similar across the four lowest quintiles of LDL reduction (23-41% ...
Ericsson C G - - 1998
Bezafibrate is a latest generation fibrate derivative that substantially reduces total plasma cholesterol and triglyceride concentrations and increases high density lipoprotein (HDL) cholesterol. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was a double-blind, placebo-controlled trial over 5 years to assess the angiographic benefits of bezafibrate retard (400 mg. day (-1) ...
Smith S C SC - - 1998
More than 13 million individuals have coronary artery disease (CAD), and in approximately 2 million patients with congestive heart failure, CAD is the underlying cause. The cost of treating cardiovascular disease has spiraled, yet only a small percentage of the total cost is spent on preventive medical therapies and lifestyle ...
Buchwald H - - 1998
BACKGROUND: In 1990, when the Program on the Surgical Control of the Hyperlipidemias (POSCH) reported its in-trial results strongly supporting the conclusion that effective lipid modification reduces progression of atherosclerosis, the differences for the end points of overall mortality and mortality from atherosclerotic coronary heart disease (ACHD) did not reach ...
Hobbs G A - - 1998
Only a few simple lipoprotein(a) [Lp(a)] assays are available in kit form for use in clinical laboratories. The present study compares the analytical and clinical performance of a mechanized immunonephelometric method to enzyme-linked immunosorbent assay. Clinical performance was evaluated by measuring lipoprotein markers in 191 patients, with the extent of ...
Páramo J A - - 1998
BACKGROUND AND OBJECTIVE: The control of well-known atherosclerotic risk factors represents the optimal strategy in the prevention of acute coronary syndromes. It was the aim of this work to analyze the effects of a long-term cardiac rehabilitation program on the changes of fibrinolysis parameters and plasma lipid profile in coronary ...
Stone N J NJ Northwestern University School of Medicine, Chicago, Illinois, - - 1998
In 1995, the latest year for which statistics are available, heart disease, cancer, and stroke continued to be the three leading causes of death in the United States. Notably, however, a wealth of experience has confirmed that hygienic interventions such as diet, exercise, weight loss, and smoking cessation can reduce ...
Vogel R A RA Division of Cardiology, University of Maryland School of Medicine, Baltimore, - - 1998
More than 10 million individuals in the United States currently have symptomatic coronary artery disease (CAD). Asymptomatic CAD is even more prevalent. CAD in the United States is responsible for approximately 1.5 million myocardial infarctions, 500,000 deaths, and a total economic burden in excess of $120 billion annually. Fortunately, CAD ...
Gazzaruso C - - 1998
We investigated Lp(a) levels and apo(a) polymorphism in relation to the severity of coronary artery disease, expressed both by the number of coronary arteries stenosed and three different coronary scoring systems. In a sample of 267 patients with coronary artery disease, a Mono-, Bi- or Multi-vessel coronary stenosis was documented ...
Hutchison B - - 1998
To validate a self administered postal questionnaire appraising risk of coronary heart disease. To determine whether use of this questionnaire increased the percentage of people at high risk of coronary heart disease and decreased the percentage of people at low risk who had their cholesterol concentration measured. Validation was by ...
Lansky A J - - 1998
Despite the success of coronary interventions in the treatment of stenosis due to coronary atherosclerosis, it behooves cardiologists to treat the underlying disease by decreasing patients' cholesterol levels. Intravascular ultrasound has made it possible to detect plaque accumulation not visible on angiography. Although advanced lesions that are fibrous and calcific ...
Saku K - - 1998
A 62-year-old man with old myocardial infarction and familial hypercholesterolemia was treated by both probucol and low-density lipoprotein (LDL) apheresis. Coronary angiography was performed before and after 3.5 years of LDL apheresis treatment, and no new lesion or progression of coronary atherosclerosis was observed. LDL apheresis drastically reduced the serum ...
Tzivoni D - - 1998
Myocardial blood flow in patients with coronary artery disease depends on the severity of the coronary narrowings and the functional status of the coronary vessels. Coronary atherosclerotic plaques, which contain high concentrations of lipids, are more sensitive to change in coronary tone. The increased tendency of these active plaques for ...
Borén J - - 1998
The apo B gene is expressed in the human heart and in the hearts of human apo B transgenic mice generated with large genomic clones spanning the human apo B gene. [35S]Methionine metabolic labeling experiments demonstrated that apo B100-containing lipoproteins are secreted by human heart tissue and by human apo ...
Schwartz G G - - 1998
The goal of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study is to determine whether early, rapid, and profound cholesterol lowering therapy with atorvastatin can reduce early recurrent ischemic events in patients with unstable angina or non-Q-wave acute myocardial infarction. Within 1 to 4 days of hospitalization for ...
Båvenholm P - - 1998
AIMS: To assess determinants of coronary artery disease progression in men with previous myocardial infarction. METHODS AND RESULTS: A total of 102 unselected non-diabetic Swedish men (age 40.4 +/- 3.6, range 23-44 years) entered the study 3-6 months after a first myocardial infarction. The programme included metabolic and haemostatic investigations ...
Wang T D - - 1998
Several large-scale clinical trials have shown that lipid-lowering interventions are associated with reduced coronary events and mortality. However, whether dyslipidemias have a detrimental effect on the evolution of myocardial infarction (MI) is still unknown. To examine whether dyslipidemias can aggravate myocardial vulnerability following MI, 165 patients with a first MI ...
Hunninghake D B - - 1998
Hypercholesterolemia, particularly an elevated level of low-density lipoprotein (LDL) cholesterol, is an unarguably established risk factor for coronary artery disease (CAD). It is equally well established that lowering LDL cholesterol levels will decrease CAD-related morbidity and mortality in patients with established CAD. Although lipid-lowering therapy is known to retard the ...
Gotto A M AM - - 1998
A number of recent clinical trials have clearly demonstrated the efficacy of cholesterol lowering as a risk-reduction strategy for the primary and secondary prevention of coronary artery disease (CAD). The Scandinavian Simvastatin Survival Study (4S), the West of Scotland Coronary Prevention Study (WOSCOPS), and the Cholesterol and Recurrent Events (CARE) ...
Eisenberg D A - - 1998
Atherosclerotic vascular disease is the major cause of death and disability in adult men and women living in the United States, where 13-14 million adults have a history of coronary artery disease (CAD). One-third of the 1.5 million individuals who experience a myocardial infarction (MI) each year will die and ...
Wood D - - 1998
European and American recommendations for coronary heart disease prevention put patients with clinically manifest coronary heart disease, or other major atherosclerotic disease, as the top priority for prevention. Coronary patients should have professional support to stop smoking, eat a healthier diet (reduce the dietary intake of fat to 30% or ...
Ullrich H - - 1998
Lipoprotein(a) (Lp[a]) is associated with an increased cardiovascular risk. It is similar to low-density lipoprotein with an additional molecule of apo A covalently linked to apo B-100 by one disulfide bridge. Apo A is highly homologous to plasminogen. The kringle 4 motive of plasminogen is repeated between 10 and 40 ...
Eisenberg D - - 1998
Patients with prior manifestations of cardiovascular disease account for about 50% of all myocardial infarctions and 70% of deaths due to coronary disease. The benefits of lowering elevated cholesterol levels in patients with coronary disease are well documented. Recent clinical trials indicate that these benefits, in terms of reduced risk ...
Kuivenhoven J A - - 1998
BACKGROUND: The high-density lipoprotein (HDL) cholesterol concentration is inversely related to the risk of coronary artery disease. The cholesteryl ester transfer protein (CETP) has a central role in the metabolism of this lipoprotein and may therefore alter the susceptibility to atherosclerosis. METHODS: The DNA of 807 men with angiographically documented ...
Suzukawa M - - 1998
Supplementation of LDL with vitamin E is thought to protect LDL from oxidative modification and prevent the development of atherosclerosis. Large epidemiological studies have revealed that vitamin E levels in plasma are inversely correlated to the incidence of coronary heart disease. Double-blind placebo-controlled trials have reported that supplementation with vitamin ...
Attebring M F - - 1998
Various risk indicators associated with recurrence of a new ischemic event among patients with coronary artery disease are described and the impact of the implementation of a secondary preventive program on such risk indicators is evaluated. At Sahlgrenska Hospital in Göteborg 293 consecutive patients under the age of 70 years ...
Sato A - - 1998
The cholesterol, triglyceride, and apolipoprotein B content of very low-, intermediate-, low-, and high-density lipoprotein fractions (separated by ultracentrifugation) and plasma were measured in healthy controls and patients with atherothrombotic infarction (26), lacunar infarction (26), and brain hemorrhage (14). In both atherothrombotic and lacunar infarction, increased plasma and low-density lipoprotein ...
Holvoet P - - 1998
Oxidative modification of LDL may occur via mechanisms, which are either dependent or independent of lipid peroxidation. Peroxidation of lipids in LDL, either initiated by radicals or catalysed by myeloperoxidase, results in the generation of aldehydes which substitute lysine residues in the apolipoprotein B-100 moiety and thus in the generation ...
Froom J - - 1998
BACKGROUND: As part of the National Cholesterol Education Program (NCEP) two expert panel reports (1988, 1993) recommend serum cholesterol measurements in all adults aged 20 years and older and cholesterol-lowering treatment for those with abnormal levels. METHODS: All major drug intervention trials for primary prevention of coronary heart disease were ...
Danielsen R - - 1998
Fibrinogen (FBG) and total coagulation factor VII (FVIIc) concentrations are higher in those patients with coronary artery disease who are at increased future risk of acute ischemic events. The relationship between activated factor VII (FVIIa) and cardiovascular events, however, has not been intensively studied. Data were collected from 401 consecutive ...
Cucherat M - - 1998
Hypercholesterolemia or hypertension are continuous risk factors for coronary heart disease. When a preventive action is carried out against such a risk factor, it is necessary to specify a risk factor level value, named the treatment threshold, above which a subject should be treated. But a non-arbitrary determination of this ...
Deslypere J P - - 1998
Lowering serum lipid levels prevents myocardial infarctions. But are we targeting the right lipoproteins in our preventive therapy? Are we getting the maximum benefit? Triglycerides certainly deserve more attention than they have yet received. Most of the trials of lipid-lowering therapy have ignored them and this omission may explain the ...
Jacobson T A - - 1997
To more efficiently reduce the risk of coronary heart disease with lipid lowering therapy, cost effectiveness analysis offers an important tool to best determine how to allocate inherently limited resources to improve the health of both individuals and society. Formal economic analysis of the most recent clinical trials with the ...
Meyers D G - - 1997
Much effort by the national cholesterol education program (NCEP) and others have been made to induce physicians to screen for and treat lipid abnormalities in patients with coronary heart disease. We measured the effect of these efforts in a single group of cardiovascular specialists. We reviewed 20 percent of applicable ...
< 15 16 17 18 19 20 21 22 23 24 25 >